Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 9

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1B
Chunk 9
---
,000
    )

    (100
    )%

    Total other income (loss), net

    42,693

    (252,274
    )

    294,967

    NM*

    Income (loss) before income tax expense

    260,774

    (520,098
    )

    780,872

    NM*

    Income tax expense

    25,535

    15,879

    9,656

    61
    %

    Net income (loss)
     
    $
    235,239

    $
    (535,977
    )
     
    $
    771,216

    NM*

    Earnings (loss) per share:

    Basic
     
    $
    2.47

    $
    (5.80
    )
     
    $
    8.27

    NM*

    Diluted
     
    $
    2.34

    $
    (5.80
    )
     
    $
    8.14

    NM*

* NM: not meaningful

Revenues

The following table summarizes the components of our net product revenues, by product, for the periods indicated:

    For the Year Ended December 31,

    2024

    2023

    Change

    Change

    (in thousands)

    $

    %

    PMO Products
     
    $
    967,169

    $
    944,520

    $
    22,649

    2
    %

    ELEVIDYS

    820,791

    200,356

    620,435

    NM*

    Products, net
     
    $
    1,787,960

    $
    1,144,876

    $
    643,084

    56
    %

* NM: not meaningful

Net product revenues for our products for 2024 increased by $643.1 million, or 56%, compared with 2023. The increase primarily reflects an increase in net product revenues of ELEVIDYS of $620.4 million in 2024 as a result of its initial FDA approval in June 2023 and subsequent expanded label approval in June 2024.

The following table summarizes the components of our collaboration and other revenues for the periods indicated:

-74-

    For the Year Ended December 31,

    2024